Afatinib versus cisplatin plus gemcitabine for first–line treatment of Asian patients with advanced non–small–cell lung cancer harbouring EGFR mutations (LUX–Lung 6): an open–label, randomised phase 3 trial
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest